Establishing the Melbourne injecting drug user cohort study (MIX): rationale, methods, and baseline and twelve-month follow-up results
1 Centre for Population Health, Burnet Institute, 85 Commercial Rd, Melbourne, VIC 3004, Australia
2 Department of Epidemiology and Preventive Medicine, Monash University, 99 Commercial Rd, Melbourne, VIC 3004, Australia
3 Kirby Institute, University of New South Wales, Corner Boundary and West Streets, Darlinghurst, NSW 3020, Australia
4 National Drug Research Institute, Curtin University, 54-62 Gertrude St, Fitzroy, VIC 3065, Australia
5 Centre for Health Policy, Programs and Economics, School of Population Health, University of Melbourne, Level 5, 207 Bouverie St, Melbourne, VIC 3010, Australia
6 National Drug and Alcohol Research Centre, University of New South Wales, 22-32 King St, Randwick, NSW 2031, Australia
7 Urban Health Research Initiative, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC V6Z 1Y6, Canada
8 Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada
9 School of Social & Community Medicine, University of Bristol, Canynge Hall, Bristol BS8 2PS, United Kingdom
Harm Reduction Journal 2013, 10:11 doi:10.1186/1477-7517-10-11Published: 21 June 2013
Cohort studies provide an excellent opportunity to monitor changes in behaviour and disease transmission over time. In Australia, cohort studies of people who inject drugs (PWID) have generally focused on older, in-treatment injectors, with only limited outcome measure data collected. In this study we specifically sought to recruit a sample of younger, largely out-of-treatment PWID, in order to study the trajectories of their drug use over time.
Respondent driven sampling, traditional snowball sampling and street outreach methods were used to recruit heroin and amphetamine injectors from one outer-urban and two inner-urban regions of Melbourne, Australia. Information was collected on participants’ demographic and social characteristics, drug use characteristics, drug market access patterns, health and social functioning, and health service utilisation. Participants are followed-up on an annual basis.
688 PWID were recruited into the study. At baseline, the median age of participants was 27.6 years (IQR: 24.4 years – 29.6 years) and two-thirds (67%) were male. Participants reported injecting for a median of 10.2 years (range: 1.5 months – 21.2 years), with 11% having injected for three years or less. Limited education, unemployment and previous incarceration were common. The majority of participants (82%) reported recent heroin injection, and one third reported being enrolled in Opioid Substitution Therapy (OST) at recruitment. At 12 months follow-up 458 participants (71% of eligible participants) were retained in the study. There were few differences in demographic and drug-use characteristics of those lost to follow-up compared with those retained in the study, with attrition significantly associated with recruitment at an inner-urban location, male gender, and providing incomplete contact information at baseline.
Our efforts to recruit a sample of largely out-of-treatment PWID were limited by drug market characteristics at the time, where fluctuating heroin availability has led to large numbers of PWID accessing low-threshold OST. Nevertheless, this study of Australian injectors will provide valuable data on the natural history of drug use, along with risk and protective factors for adverse health outcomes associated with injecting drug use. Comprehensive follow-up procedures have led to good participant retention and limited attrition bias.